Myriad Genetics' stock continues to fall as investors fear poor results from a late-stage study of Flurizan for Alzheimer's. A phase II study of the drug found that Flurizan didn't benefit those with a moderate form of the disease, and Myriad designed the Phase III trial to focus on those with mild Alzheimer's. Investors aren't wild about the approach. "In a rush to Phase III, Myriad has made several critical mistakes, in our view," said one analyst.
- read the report for more